Christian Weyer Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Christian Weyer.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Christian Weyer. Christian Weyer is a SVP, Research & Development in AMYLIN PHARMACEUTICALS INC ($AMLN) and a EVP Research and Development in INTERCEPT PHARMACEUTICALS INC ($ICPT) and a EVP, Research & Development in INTERCEPT PHARMACEUTICALS, INC. ($ICPT) and a See Remarks in FATE THERAPEUTICS INC ($FATE).
Address: 9360 TOWNE CENTRE DR SAN DIEGO 92121 CA
Companies in which Christian Weyer is an Insider
AMYLIN PHARMACEUTICALS INC
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Christian Weyer: SVP, Research & Development
Holdings: 0 shares
Latest Transaction: Aug 10 2012
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
FATE THERAPEUTICS INC
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Christian Weyer: See Remarks
Holdings: 30,429 shares
Current Value: $85,201
Latest Transaction: Apr 14 2015
$FATE Market Capitalization: $95.27M
$FATE Previous Close: $2.80
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
INTERCEPT PHARMACEUTICALS, INC.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Christian Weyer: EVP, Research & Development, EVP Research and Development
Holdings: 27,341 shares
Current Value: $3,105,117
Latest Transaction: Apr 05 2021
$ICPT Market Capitalization: $2.80B
$ICPT Previous Close: $113.57
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Christian Weyer
Sentiment: All, AMLN, FATE, ICPT
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 05 2021 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 24.28 | 46 | 1,117 | 27,341 | 27.4 K to 27.3 K (-0.17 %) |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | A | 29.46 | 19,700 | 580,362 | 19,700 | |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Grant | A | 0.00 | 12,600 | 0 | 27,744 | 15.1 K to 27.7 K (+83.20 %) |
| Nov 30 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 37.27 | 357 | 13,305 | 15,977 | 16.3 K to 16 K (-2.19 %) |
| Aug 31 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 48.81 | 357 | 17,425 | 16,380 | 16.7 K to 16.4 K (-2.13 %) |
| Aug 31 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 48.81 | 357 | 17,425 | 16,380 | 16.7 K to 16.4 K (-2.13 %) |
| Jul 06 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 46.52 | 46 | 2,140 | 16,737 | 16.8 K to 16.7 K (-0.27 %) |